Delving into the Latest Updates on Prostate cancer vaccine(FK Biotecnologia SA) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

VAP, VAP-FK

Target

HLA class II antigen

Action

modulators

Mechanism

HLA class II antigen modulators

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication-

Inactive Indication

Prostatic Cancer

Originator Organization

FK Biotecnologia SA

Active Organization-

Inactive Organization

FK Biotecnologia SA

Universidade Federal do Rio Grande do Sul

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Many angiotensin-converting enzyme (ACE) inhibitory peptides (ACEIPs) have been discovered in milk casein hydrolysates, but their inhibitory mechanisms mostly remain unclear. Among these peptides, the tripeptides with proline at the C-terminus are valuable for research due to their stability and absorbability. Analyzing them is time-consuming as no effective screening methods exist. To address this, we constructed a quantitative structure-activity relationship (QSAR) model (R² = 0.862) and successfully identified a novel ACEIP, Val-Ala-Pro (VAP), from milk casein hydrolysates. Subsequent analysis utilizing isothermal titration calorimetry, multi-spectroscopy, and molecular simulations revealed that VAP is a non-competitive inhibitor with significant ACE activity (IC₅₀ = 1.93 ± 0.17 μM). It binds to key ACE sites (Asn-30, Glu-107, Val-315, Trp-321, and Phe-476) via non-covalent interactions. Moreover, VAP is absorbed in the intestine through paracellular diffusion and the PepT1 pathway. Overall, this work has advanced the research and development of ACEIPs derived from milk casein hydrolysates.

01 Aug 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Effects of polypeptides derived from velvet antler on D-gal induced brain aging model

Article

Author: Pei, Hongyan ; He, Zhongmei ; Li, Jianming ; Geng, Jianan ; Zhao, Yan ; Chen, Sihan ; Zong, Ying ; Du, Rui

AIM:

We aimed to explore the protective effects and mechanism of velvet antler polypeptides (VAP) against D-galactose (D-gal)-induced aging model in vivo and in vitro.

METHODS:

The mouse model of mild cognitive impairment was established by intraperitoneal injection of D-gal (400 mg/kg). After gavage of VAP (50 and 200 mg/kg) for 4 weeks, the water maze behavior test was performed. HIF - 1α and BDNF expression levels in hippocampus were detected by immunofluorescence, neuron damage was detected by HE and Nissl staining, and inflammatory factors and oxidative stress were detected by Elisa. Protein expression was detected by western blot. The aging model of HT22 cells was established in vitro by D-gal (40 mg/L), the total enzymatic hydrolysis products were fractionated, and the best peptide (VAP-III) was screened out. The effects of VAP-III (200 and 600 μg/mL) on D-gal induced apoptosis, oxidative stress and neuroinflammation were detected. Then, Nano LC-MS/MS and molecular docking were used to predict the binding activity of VAP-III to BDNF, PI3K and Akt.

RESULTS:

VAP can improve D-gal-induced neuronal damage and inhibit the production of pro-inflammatory factors and oxidative stress-related products. VAP can promote the activation of BDNF/PI3K/Akt signaling pathway.

CONCLUSION:

VAP may play a neuroprotective role by regulating the BDNF/PI3K/Akt signaling pathway.

01 Jul 2025·MEDICINE & SCIENCE IN SPORTS & EXERCISE

Advanced Footwear Technology, But Not Acute Ingestion of a Ketone Monoester, Improves Running Economy in Middle- and Long-Distance Runners

Article

Author: EGAN, BRENDAN ; DEVENNEY, SIMON ; BRADY, AIDAN J. ; MOYNAGH, MEGAN B.

ABSTRACT:

Purpose:

This study examined the separate and combined effects of advanced footwear technology and acute ingestion of a ketone monoester on running economy (RE), time to exhaustion, and other metabolic and cardiorespiratory parameters.

Methods:

In a four-condition, placebo-controlled, randomized crossover design, 18 middle- and long-distance runners (male/female = 10/8, V̇O2peak = 59.4 ± 7.2 mL·kg−1·min−1) completed five 8-min stages of submaximal running (male = 10–14 km⋅h−1, female = 9–13 km⋅h−1) on a motorized treadmill, immediately followed by a ramp test to volitional exhaustion. Participants consumed 500 mL of either a 10% carbohydrate solution (CHO) or 500 mg·kg−1 body mass of an (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester with flavored water (KME) 20 min before exercise, and an additional 300 mL of the 10% carbohydrate solution or 250 mg·kg−1 body mass of KME during exercise, while wearing either Nike Pegasus Turbo (PEG) or Nike ZoomX Vaporfly Next% 3 (VAP) running shoes. The four randomized conditions were PEG + CHO, PEG + KME, VAP + CHO, and VAP + KME.

Results:

RE was significantly improved during the third and the fourth submaximal running stages in VAP + CHO and VAP + KME compared with PEG + CHO and PEG + KME (all P < 0.05, ES = 0.53–0.84). RE was also improved during the fifth submaximal running stage in VAP + KME compared with PEG + CHO, and in VAP + CHO and VAP + KME compared with PEG + KME (all P < 0.05, ES = 0.56–0.66). No differences in RE were found between CHO and KME conditions. Time to exhaustion was significantly longer in VAP + CHO (381 ± 125 s) than PEG + CHO (356 ± 140 s, P = 0.023, ES = 0.18) and PEG + KME (329 ± 131 s, P < 0.001, ES = 0.40) and in VAP + KME (375 ± 125 s) than PEG + KME (P < 0.001, ES = 0.35).

Conclusions:

Advanced footwear technology, but not the acute ingestion of a ketone monoester, improved the RE of trained male and female middle- and long-distance runners at submaximal running speeds.

100 Deals associated with Prostate cancer vaccine(FK Biotecnologia SA)

Login to view more data